Pelthos Therapeutics (PTHS)
:PTHS
Want to see PTHS full AI Analyst Report?
PTHS Stock Chart & Stats
$23.02
--
Market closed
$23.02
--
Day’s Range― - ―
52-Week Range$9.00 - $54.29
Previous CloseN/A
VolumeN/A
Average Volume (3M)30.94K
Market Cap
$92.66M
Enterprise Value$37.99M
Total Cash (Recent Filing)$32.23M
Total Debt (Recent Filing)$52.93M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 24, 2026EPS Estimate
-2.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-40.69
Shares Outstanding3,475,645
10 Day Avg. Volume22,109
30 Day Avg. Volume30,941
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.50
Price to Sales (P/S)3.47
P/FCF Ratio-2.57
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit2.08
Enterprise Value/Ebitda-0.96
Forecast
1Y Price Target
$57.71Price Target Upside150.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-9.77
Revenue Forecast (FY)$60.82M
Bulls Say, Bears Say
Bulls Say
Market AccessBroader commercial and Medicaid coverage and new pharmacy benefit contracts improve patient access and should support continued prescription growth.
Market DemandShift from inventory stocking to dispensed prescriptions indicates real patient demand for the product and supports a more durable revenue profile.
Prescriber AdoptionExpanding prescriber adoption across dermatology and pediatric settings, with early evidence of repeat use, supports broader uptake and deeper market penetration.
Bears Say
Commercial ExecutionCommercial and launch risks for Zelsuvmi and recently acquired products could limit sales growth and slow market adoption despite clinical advantages.
Financial ObligationsHigher selling and administrative expenses combined with the company's term loan obligations raise fixed costs and can compress profitability.
Reimbursement PressureIncreasing payer contracting and higher gross-to-net pressures could meaningfully reduce net revenue as the product scales.
Pelthos Therapeutics News
PTHS FAQ
What was Pelthos Therapeutics’s price range in the past 12 months?
Pelthos Therapeutics lowest stock price was $9.00 and its highest was $54.29 in the past 12 months.
What is Pelthos Therapeutics’s market cap?
Pelthos Therapeutics’s market cap is $92.66M.
When is Pelthos Therapeutics’s upcoming earnings report date?
Pelthos Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 91 days.
How were Pelthos Therapeutics’s earnings last quarter?
Pelthos Therapeutics released its earnings results on May 14, 2026. The company reported -$3.09 earnings per share for the quarter, beating the consensus estimate of -$3.45 by $0.36.
Is Pelthos Therapeutics overvalued?
According to Wall Street analysts Pelthos Therapeutics’s price is currently Undervalued.
Does Pelthos Therapeutics pay dividends?
Pelthos Therapeutics does not currently pay dividends.
What is Pelthos Therapeutics’s EPS estimate?
Pelthos Therapeutics’s EPS estimate is -2.82.
How many shares outstanding does Pelthos Therapeutics have?
Pelthos Therapeutics has 3,475,645 shares outstanding.
What happened to Pelthos Therapeutics’s price movement after its last earnings report?
Pelthos Therapeutics reported an EPS of -$3.09 in its last earnings report, beating expectations of -$3.45. Following the earnings report the stock price went up 6.459%.
Which hedge fund is a major shareholder of Pelthos Therapeutics?
Currently, no hedge funds are holding shares in PTHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pelthos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.71 (150.71% Upside)
$57.71 (150.71% Upside)
Blogger Sentiment
Bullish
PTHS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 201.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
315.91%
12-Months-Change
Fundamentals
Return on Equity
-164.11%
Trailing 12-Months
Asset Growth
9999.00%
Trailing 12-Months
Company Description
Pelthos Therapeutics
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
PTHS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive commercialization story: strong prescription growth (25% QoQ), 17% revenue growth QoQ, expanding prescriber base and payer access, successful PBM engagement, and improved liquidity from a debt draw. These operational and commercial wins are tempered by ongoing unprofitable quarterly results, negative adjusted EBITDA, rising SG&A and interest costs, anticipated higher gross-to-net pressures (mid-30s), and some inventory accounting timing effects. On balance, the company shows solid early launch traction and strengthened financial flexibility while still investing heavily toward profitability and additional product launches.View all PTHS earnings summariesPTHS Stock 12 Month Forecast
Average Price Target
$57.71
▲(150.71% Upside)
Technical Analysis
Immunic
―
Fortress Biotech
―
Verrica Pharmaceuticals
―
Instil Bio
―
Tevogen Bio Holdings
―